2020-12-28,Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%
2020-12-22,Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
2020-12-10,Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
2020-12-08,Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
2020-11-12,Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
2020-11-09,Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
2020-09-14,"Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020"
2020-09-09,Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
2020-08-19,Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
2020-08-12,Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
2020-08-10,Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
2020-08-06,Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
2020-06-30,Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
2020-06-17,We're Excited To See How Monopar Therapeutics (NASDAQ:MNPR) Uses Its Cash Hoard To Grow
2020-06-16,Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19
2020-06-09,Monopar Therapeutics (MNPR) Catches Eye: Stock Jumps 11.2%
2020-05-07,Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
2020-03-27,Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
2020-02-18,Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
2019-12-23,Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
2019-12-20,Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
2019-12-18,Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
